乌司奴单抗谷浓度与克罗恩病患者临床、生物标志物及内镜结局的关联
研究纳入62例难治或不耐受TNF拮抗剂的克罗恩病患者,接受乌司奴单抗治疗。第26周或以后,80.7%患者有临床应答,66.1%临床缓解,58.9%内镜应答,19.6%内镜缓解。乌司奴单抗谷浓度高于4.5 μg/mL者内镜应答比例更高(75.9% vs 40.7%,P=.008),平均CRP更低(12.6 mg/L vs 23.9 mg/L,P=.04)。
要点
- 第26周或以后乌司奴单抗谷浓度高于4.5 μg/mL与更高的内镜应答比例相关(75.9% vs 40.7%,P=.008)。
- 谷浓度高于4.5 μg/mL者平均CRP低于低于此水平者(12.6 mg/L vs 23.9 mg/L,P=.04)。
- 所有患者均未检测到抗乌司奴单抗抗体。
核心结论
- 乌司奴单抗对TNF拮抗剂无效或不耐受的克罗恩病患者有效。
- 第26周或以后维持期乌司奴单抗谷浓度高于4.5 μg/mL与生物标志物降低及内镜应答相关。
研究设计与样本
- 研究招募62例对TNF拮抗剂难治或不耐受的克罗恩病患者,于2014年4月至2015年9月接受乌司奴单抗治疗。
- 诱导期在第0、1、2周皮下注射90 mg乌司奴单抗,维持期每4或8周皮下注射90 mg。
- 采用前瞻性纵向队列和横断面队列,在诱导后第10周及维持期第26周或以后评估结局、谷浓度及抗药抗体,并合并两个维持队列数据进行分析。
主要发现
- 第26周或以后,80.7%患者有临床应答,66.1%临床缓解,50.0%无激素临床缓解,58.9%内镜应答,19.6%内镜缓解。
- 有内镜应答者平均谷浓度为4.7 μg/mL,无内镜应答者为3.8 μg/mL(P=.03)。
- 第26周或以后谷浓度高于4.5 μg/mL者内镜应答比例为75.9%,低于此水平者为40.7%(P=.008)。
- 第26周或以后谷浓度高于4.5 μg/mL者平均CRP为12.6 mg/L,低于此水平者为23.9 mg/L(P=.04)。
- 所有患者均未检测到抗乌司奴单抗抗体。
关键数值与推荐
- 第26周或以后乌司奴单抗谷浓度的最佳阈值为4.5 μg/mL(曲线下面积0.67)。
- 临床应答定义为Harvey Bradshaw指数评分降低3分或以上。
- 临床缓解定义为Harvey Bradshaw指数评分<5。
- 生物标志物正常化定义为血清CRP低于5 mg/L或粪钙卫蛋白低于200 μg/g。
- 内镜应答定义为克罗恩病简化内镜评分降低50%或以上;内镜缓解定义为克罗恩病简化内镜评分≤2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of tumor necrosis factor (TNF) antagonists and presence of anti-drug antibodies are associated with important clinical and endoscopic outcomes. We investigated associations between trough concentrations of ustekinumab and clinical, biomarker, and endoscopic outcomes of real-world patients with CD. METHODS: We recruited 62 patients with CD who were either refractory or intolerant to TNF antagonists, treated with ustekinumab from April 2014 to September 2015. Patients received 90 mg of ustekinumab subcutaneously at weeks 0, 1, and 2 during induction and 90 mg every 4 or 8 weeks during maintenance. Clinical, biomarker, and endoscopic outcomes, trough concentrations of ustekinumab, and anti-drug antibodies were assessed at both week 10 postinduction therapy and at week 26 or later during maintenance therapy in a prospective longitudinal patient cohort or at week 26 or later during maintenance therapy in a cross-sectional patient cohort. Analysis was performed on data combined from both maintenance cohorts, which had similar outcomes at week 26 or later. A primary analysis determined if ustekinumab drug trough concentrations were associated with clinical response (reduction in Harvey Bradshaw Index score of 3 or greater), clinical remission (Harvey Bradshaw Index score <5), steroid-free clinical remission, biomarker (serum level of C-reactive protein [CRP] or level of fecal calprotectin) reduction, biomarker normalization (serum level of CRP below 5 mg/L or level of fecal calprotectin below 200 μg/g), endoscopic response (simple endoscopic score for CD reduced by 50% or more), or endoscopic remission (simple endoscopic score for CD of 2 or less). RESULTS: At week 26 or beyond, 80.7% of patients had a clinical response, 66.1% were in clinical remission, 50.0% were in steroid-free clinical remission, 58.9% had an endoscopic response, and 19.6% were in endoscopic remission. The mean trough concentration of ustekinumab at this time point was higher in patients with an endoscopic response (4.7 μg/mL) than without (3.8 ug/mL; P = .03). An optimal ustekinumab threshold trough concentration at week 26 or later was found to be 4.5 μg/mL (area under the curve, 0.67). A greater proportion of patients with trough concentrations of ustekinumab above 4.5 μg/mL at week 26 or later had an endoscopic response (75.9%) than did patients with trough concentrations below this level (40.7%; P = .008). Patients with trough concentrations of ustekinumab above 4.5 μg/mL at week 26 or later also had a lower mean level of CRP (12.6 mg/L) than did patients with trough concentrations below this level (mean level of CRP, 23.9 mg/L; P = .04). We did not detect antibodies against ustekinumab in any patient. CONCLUSIONS: Ustekinumab therapy was effective in patients with CD who had not responded to or were intolerant to treatment with a TNF antagonist. Maintenance trough concentrations of ustekinumab above 4.5 μg/mL at 26 weeks or later were associated with biomarker reduction and endoscopic response.
引用
- Battat R, Kopylov U, Bessissow T, et al. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2017. PMID: 28365485. doi:10.1016/j.cgh.2017.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。